STOCK TITAN

Lincoln Alternative Strategies reports 0% Calidi Biotherapeutics (CLDI) stake

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Calidi Biotherapeutics, Inc. investor Lincoln Alternative Strategies LLC filed an amended Schedule 13G to report that it no longer beneficially owns any shares of Calidi common stock. The filing shows 0 shares with 0% of the class, with no sole or shared voting or dispositive power.

The amendment reflects ownership of 5 percent or less of the common stock, par value $0.0001 per share, of Calidi Biotherapeutics. Lincoln Alternative Strategies is organized in Delaware, and the certification states the securities were not acquired to change or influence control of the company.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



Lincoln Alternative Strategies LLC
Signature:/s/ Stephen Temes
Name/Title:Stephen Temes/Managing Member
Date:02/10/2026
Calidi Biotherapeutics Inc

NYSE:CLDI

CLDI Rankings

CLDI Latest News

CLDI Latest SEC Filings

CLDI Stock Data

5.92M
6.06M
20.25%
4.45%
7.06%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SAN DIEGO